Targeting the mTOR pathway: A new horizon in oral cancer treatment

•This editorial examines the critical role of the mTOR pathway in oral cancer progression and resistance to conventional therapies.•Detailed exploration of genetic and epigenetic alterations leading to hyperactivation of the mTOR pathway in oral cancer.•Discussion on the efficacy of mTOR inhibitors,...

Full description

Saved in:
Bibliographic Details
Published inOral oncology reports Vol. 11; p. 100619
Main Authors Devaraji, Mahalakshmi, Thanikachalam, Punniyakoti V.
Format Journal Article
LanguageEnglish
Published Elsevier Ltd 01.09.2024
Elsevier
Subjects
Hematology, Oncology, and Palliative Medicine
Online AccessGet full text
ISSN2772-9060
2772-9060
DOI10.1016/j.oor.2024.100619

Cover

More Information
Summary:•This editorial examines the critical role of the mTOR pathway in oral cancer progression and resistance to conventional therapies.•Detailed exploration of genetic and epigenetic alterations leading to hyperactivation of the mTOR pathway in oral cancer.•Discussion on the efficacy of mTOR inhibitors, challenges faced, and the development of second-generation inhibitors targeting both mTORC1 and mTORC2.•Insight into the promising results of combining mTOR inhibitors with other targeted agents and immune checkpoint inhibitors to enhance therapeutic efficacy.•Focusing research on dual mTORC1/mTORC2 inhibitors and biomarker identification to enhance personalized treatment for oral cancer patients.
ISSN:2772-9060
2772-9060
DOI:10.1016/j.oor.2024.100619